Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial on Feb 18, 2026 highlighting investor and acquirer preference for de-risked, late-stage biotech assets.
The company said it recently achieved key global intellectual property advancements supporting OT-101, its TGF-β antisense therapeutic platform, and holds multiple clinical- and late-stage programs in oncology and CNS indications, aligning with current M&A priorities.
Oncotelic Therapeutics (NASDAQ:OTLC) and Sapu Bioscience expanded OT-101 intellectual property to strengthen a CNS and neurology commercialization pathway. Australia allowed Parkinson’s Disease claims for OT-101 (SEQ ID NO:9) covering treatment methods and CNS delivery routes. China and Germany granted utility model patents for continuous intracranial infusion devices (CN 222693486 U; DE 21 2023 000 368.6) with device-term protection noted through 2033. The company positions these filings as a layered patent wall to support partnering, development, and long-term commercial defensibility for oncology and neurology uses.
Oncotelic Therapeutics (OTLC) reported 2025 progress and set priorities for 2026, highlighting platform validation, clinical advancement, and asset valuation.
Key 2025 achievements include unveiling the PDAOAI knowledge platform, completing a Phase 1 OT-101 combination trial, initiating first-in-human testing of IV everolimus Deciparticle (Sapu-003), multiple peer-reviewed publications, a Medicilon partnership for IND-enabling work, and an independent valuation of the GMP Bio JV pipeline at approximately $1.7 billion.
Oncotelic (OTLC) opened access to PDAOAI, its evidence-interrogation platform, and published a curated TGF-β literature corpus to a dedicated Discord research channel on Dec 22, 2025. PDAOAI embeds, clusters, and queries large biomedical datasets to surface citation-backed, testable hypotheses rather than training bespoke LLMs on proprietary data. The corpus includes more than 125,000 PubMed abstracts. The platform has supported seven peer-reviewed publications and is positioned to aid biomarker prioritization, precision trial design, and translational decision-making.
Oncotelic Therapeutics (OTLC) and Brush and Key Foundation announced a peer-reviewed publication in the International Journal of Molecular Sciences on Dec 15, 2025.
The study analyzed >7,000 patients to compare two biomarkers—DNMT3A and GMPS—in hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC). Findings show prognostic value is context-dependent, influenced by immune composition, metabolic reprogramming, and innate immune sensing in the tumor microenvironment.
The paper highlights advanced bioinformatics methods and notes the Brush and Key Foundation's role in mentoring young researchers.
Oncotelic (OTLC)-owned JV Sapu Nano announced a Deciparticle-led biomarker framework that identifies tumors likely to respond to IV Sapu003, an intravenous everolimus nanomedicine. The analysis evaluated >9,000 patient tumor samples across 20 cancer types and found a High-RICTOR / Low-RPTOR gene-expression signature linked to greater mTOR dependency and predicted sensitivity to IV Sapu003. The signature is enriched in HR+/HER2- breast cancer, lung adenocarcinoma, gastric, renal cell, ovarian, AML and T-cell malignancies. Sapu003 is reported to reduce GI accumulation by 67×, increase tumor tissue penetration, and enable biomarker-driven patient selection. Data will be presented at the 2025 San Antonio Breast Cancer Symposium (Dec 9-12, 2025).
Oncotelic (OTLC) and Sapu Nano reported new preclinical pharmacokinetic and tissue distribution data for Sapu003 (IV everolimus) on Dec 3, 2025. The data show IV Sapu003 markedly reduces gastrointestinal drug accumulation versus oral everolimus: stomach exposure down 67-fold, small intestine down 15.7-fold, and large intestine down 7.4-fold. IV dosing produced GI tissue:plasma ratios of 36–48× versus much higher ratios after oral dosing (stomach 2,448×, small intestine 750×, large intestine 323×). The release notes potential for improved tolerability, more consistent systemic exposure, and previously reported 97–98% tumor inhibition in a xenograft model, supporting a Phase I rationale in HR+/HER2- metastatic breast cancer.
Oncotelic (OTLC)-owned joint venture Sapu Nano announced Dec 2, 2025 that its proprietary Deciparticle™ platform reproducibly formulates structurally diverse hydrophobic therapeutics into precise sub-20 nm nanoparticles suitable for IV delivery.
Key findings presented at SABCS 2025: monodisperse ~15 nm Deciparticles encapsulate five macrolide mTOR inhibitors (sirolimus, temsirolimus, ridaforolimus, umirolimus, everolimus), ascomycin macrolactam tacrolimus, and peptide drugs (cyclosporine A, exenatide). Pimecrolimus produced particles above the sub-20 nm threshold, defining a steric limit.
Sapu Nano reported an ISO-5 cGMP manufacturing suite supporting one-pot bulk drug manufacturing, sterile filtration, automated fill/finish, lyophilization, tight lot-to-lot particle-size control, and the ability to support multiple INDs annually.
Oncotelic Therapeutics (OTCQB: OTLC) announced a pending major fair-value update for its 45% ownership in JV partner GMP Bio after a new independent valuation indicated a substantial increase in the asset’s worth. The company was featured in an editorial about rising biotech valuations as clinical platforms advance toward commercialization.
The release frames GAAP fair-value adjustments as investor signals that translate research progress into measurable economic impact and says the JV revaluation reinforces Oncotelic’s position in the oncology-treatment space.
Oncotelic Therapeutics (OTCQB: OTLC) on Nov 21, 2025 highlighted placement in an editorial by BioMedWire and disclosed a forthcoming GAAP fair-value remeasurement of its 45% stake in JV entity GMP Bio after a new independent valuation indicated a potential step-up in asset value.
The announcement frames fair-value remeasurements as a bridge between late-stage biotech progress and shareholder value and says the independent valuation could strengthen Oncotelic's position in oncology as the company advances the JV asset review.